[
    "rth in U.S. patent nos. 6,410,596 or 6,552,085, the disclosures of which are incorporated herein by reference in their entirety. For example, in one embodiment, sirtuin-activating compounds do not include compounds having the following formula 22:</p></p>wherein,</p>a is selected from single bonds and double bonds in trans conformation;</p>r1 is selected from H, OH, C1-6 alkoxy, COOH and COOC1-6 alkyl;</p>r2 is selected from H, OH and C1-10 alkoxy;</p>r3 is selected from the group consisting of H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl and C1-8 cycloalkyl;</p>r4 is selected from H, OH and C1-10 alkoxy;</p>r5 is selected from the group consisting of H, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl and C1-8 cycloalkyl;</p>r6 is selected from H, OH, C1-6 alkoxy, COOH and COOC1-6 alkyl;</p>r7 is selected from H, OH, C1-6 alkoxy, COOH and COOC1-6 alkyl; and is</p>Wherein at least one of R3 and R5 is selected from the group consisting of C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl and C1-8 cycloalkyl.</p>In certain embodiments, a targeted sirtuin activator, such as a SIRT1 activator, does not have any significant ability to inhibit PI 3-kinase, inhibit aldehyde reductase, and/or inhibit tyrosine protein kinase at concentrations (e.g., in vivo) effective to activate the deacetylase activity of a sirtuin, such as SIRT 1. For example, in preferred embodiments, the sirtuin activator is selected to be at least 5-fold, even more preferably at least 10-fold, 100-fold, or even 1000-fold less EC50 that activates sirtuin deacetylase activity than EC50 that inhibits one or more of aldehyde reductase and/or tyrosine protein kinase. Methods for determining PI 3-kinase activity, aldehyde reductase activity, and tyrosine kinase activity are well known in the art, and kits for performing such assays are commercially available. For PI3 kinase assays, see, e.g., U.S. patent publication No.2003/0158212, and for aldehyde reductase assays, see, e.g., U.S. patent publication No. 2002/20143017; tyrosine kinase assay kits are commercially available, for example, from Promega (Madison, Wis.; website is Promega. com.), Invitrogen (Carlsbad, CA; website is Invitrogen. com) or molecular devices (Sunnyvale, CA; website is molecular devices. com).</p>In certain embodiments, the sirtuin activator of interest does not have any significant ability to transactivate EGFR tyrosine kinase activity at a concentration (e.g., in vivo) effective to activate the sirtuin's deacetylase activity. For example, in preferred embodiments, a sirtuin activator that activates sirtuin deacetylase activity with EC50 at least 5-fold, and even more preferably at least 10-fold, 100-fold, or even 1000-fold less than EC50 that transactivates EGFR tyrosine kinase activity is selected. Methods for determining transactivation of EGFR tyrosine kinase activity are well known in the art, see, e.g., Pai et al. 289-93(2002) and Vacca et al cancer research 60: 5310-5317(2000).</p>In certain embodiments, the sirtuin activator of interest does not have any significant ability to cause coronary artery dilation at a concentration (e.g., in vivo) effective to activate the sirtuin's deacetylase activity. For example, in preferred embodiments, the sirtuin activator is selected to have an EC50 that activates sirtuin deacetylase activity that is at least 5-fold, and even more preferably at least 10-fold, 100-fold, or even 1000-fold less than EC50 for coronary artery dilation. Methods for measuring vasodilation are well known in the art, see, for example, U.S. patent publication No. 2004/0236153.</p>In certain embodiments, the sirtuin activator of interest does not have any significant spasmolytic capacity at a concentration (e.g., in vivo) effective to activate the deacetylase activity of the sirtuin. For example, in preferred embodiments, a sirtuin activator is selected that activates sirtuin deacetylase activity with an EC50 that is at least 5-fold, even more preferably at least 10-fold, 100-fold, or even 1000-fold less than the EC50 for spasmolytic effects (e.g., on gastrointestinal muscle). Methods for determining spasmolytic activity are well known in the art, see, e.g., U.S. patent publication No. 2004/0248987.</p>In certain embodiments, the sirtuin activator of interest does not have any significant ability to inhibit the liver cytochrome P4501B1(CYP) at a concentration effective to activate the deacetylase activity of the sirtuin (e.g., in vivo). For example, in preferred embodiments, a sirtuin activator that activates the sirtuin deacetylase activity with EC50 at least 5-fold, and even more preferably at least 10-fold, 100-fold, or even 1000-fold less than EC50, is selected to inhibit P4501B 1. Methods for determining the activity of cytochrome P450 are well known in the art, and kits for performing such assays are commercially available. See, for example, U.S. patents 6,420,131 and 6,335,428 and Promega (Madison, Wis.; website Promega. Com).</p>In certain embodiments, the sirtuin activator of interest does not have any significant ability to inhibit nuclear factor- \u03ba B (NF- \u03ba B) at a concentration effective to activate the sirtuin's deacetylase activity (e.g., in vivo). For example, in preferred embodiments, the sirtuin activator is selected to activate sirtuin deacetylase activity with an EC50 that is at least 5-fold, and even more preferably at least 10-fold, 100-fold, or even 1000-fold less than the EC50 that inhibits NF- \u03ba B. Methods for measuring NF-. kappa.B activity are well known in the art, and kits for performing such measurements are commercially available (e.g., from Oxford biological Research (Ann Arbor, MI; the website is oxydbellied. com)).</p>In certain embodiments, the targeted sirtuin activator does not have any significant ability to inhibit class I Histone Deacetylases (HDACs), class II HDACs, or class I and II HDACs at a concentration effective to activate the sirtuin deacetylase activity (e.g., in vivo). For example, in preferred embodiments, a sirtuin activator that activates the sirtuin deacetylase activity with EC50 at least 5-fold, even more preferably at least 10-fold, 100-fold, or even 1000-fold less than the HDAC I and/or HDAC II inhibiting EC50 is selected. Methods of assaying hdaci and/or HDACII activity are well known in the art, and kits for performing such assays are commercially available. See, for example, BioVision, Inc. (Mountain View, CA; website address BioVision. com) and Thomas Scientific (Swedesboro, NJ; website address tomassci. com).</p>In certain embodiments, a SIRT1 activator of interest does not have any significant ability to activate a SIRT1 ortholog in lower eukaryotes, particularly yeast or human pathogens, at a concentration (e.g., in vivo) effective to activate the deacetylase activity of human SIRT 1. For example, in a preferred embodiment, a SIRT1 activator that activates human SIRT1 deacetylase activity with an EC50 that is at least 5-fold, even more preferably at least 10-fold, 100-fold, or even 1000-fold less than the EC50 that activates yeast Sir2 (e.g., candida, saccharomyces cerevisiae, etc.) is selected.</p>In certain embodiments, a sirtuin-activating compound may have the ability to activate one or more situin protein homologs, e.g., one or more of human SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT 7. In other embodiments, the SIRT1 activator does not have any significant ability to activate other sirtuin protein homologs, e.g., activate one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7, at concentrations (e.g., in vivo) effective to activate the deacetylase activity of human SIRT 1. For example, an SIRT1 activator that activates EC50 of human SIRT1 deacetylase activity at least 5-fold, even more preferably at least 10-fold, 100-fold, or even 1000-fold less than EC50 that activates one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7 may be selected.</p>In certain embodiments, fat mobilization can be modulated with SIRT3 and SIRT4 modulators. For example, SIRT3 and/or SIRT4 activators may be used to induce fat mobilization and may be used to treat, for example, obesity and insulin resistance disorders.</p>In other embodiments, the sirtuin activator of interest does not have any significant ability to activate the deacetylase activity of the sirtuin (e.g., in vivo) at a concentration effective to: inhibition of protein kinases; phosphorylating a mitogen-activated protein (MAP) kinase; inhibition of catalytic or transcriptional activity of a cyclooxygenase enzyme, such as COX-2; inhibition of Nitric Oxide Synthase (iNOS); or inhibiting the adhesion of platelets to type I collagen. For example, in preferred embodiments, the sirtuin activator is selected to have an EC50 that activates sirtuin deacetylase activity that is at least 5-fold, and even more preferably at least 10-fold, 100-fold, or even 1000-fold less than EC50 that performs any of the activities described above. Methods for determining protein kinase activity, cyclooxygenase activity, nitric oxide synthase activity, and platelet adhesion activity are well known in the art, and kits for performing such assays are commercially available. For protein kinase assay kits see, e.g., Promega (Madison, Wis.; website is Promega. com); invitrogen (Carlsbad, CA; the website is invitogen.com); molecular Devices (Sunnyvale, CA; website: Molecular Devices. com) or Assay Designs (Ann Arbor MI; website: Assay Designs. com); for cyclooxygenase assay kits see, e.g., Amersham biosciences (Piscataway, NJ; website: amersham biosciences. com); for nitric oxide synthase assay kits see, e.g., Amersham Biosciences (Piscataway, NJ; website: Amersham Biosciences. com) and R &amp; DSsystems (Minneapolis, website: rndsystems. com); for platelet adhesion assays, see, e.g., U.S. patent nos.5,321,010; 6,849,290, and 6,774,107.</p>Sirtuin-activating compounds described herein may be administered alone or in combination with other compounds. Other compounds may be other sirtuins and/or AMPK activators. For example, the red wine extract, Longevinex, contains, in addition to resveratrol, other sirtuin activators such as quercetin, which are particularly potent agents for mobilizing fat. The LongevinexTM is available on the web at www.longevinex.com.</p>The combination regimen may also include drugs or compounds useful in the treatment of obesity and/or diabetes.<",
    "irtuin in the cell. Protein levels may be reduced according to methods known in the art. For example, sirtuin-targeting sirnas and antisense or ribozymes can be expressed in cells. Dominant negative mutants, such as those that are not deacetylated, may be used. For example, Luo et al (2001) Cell 107: 137, mutant H363Y of SIRT 1. Alternatively, agents that inhibit transcription may be used.</p>In other embodiments, a compound described herein, such as a sirtuin activator or inhibitor, does not have significant or detectable antioxidant activity as determined by standard assays well known in the art. For example, the compounds do not significantly scavenge free radicals, such as the O2 radical. The compound may have less than about 2,3, 5, 10, 30, or 100 times the antioxidant activity relative to another compound, such as resveratrol.</p>The compound may also have a value of about 10<sup>-9</sup>M\u300110<sup>-10</sup>M\u300110<sup>-11</sup>M\u300110<sup>-12</sup>M or less binding affinity to the sirtuin. The compound can reduce the Km of the sirtuin for its substrate or NAD + by a factor of at least about 2,3, 4,5, 10, 20, 30, 50, or 100. The compound can increase the Vmax of the sirtuin by a factor of at least about 2,3, 4,5, 10, 20, 30, 50, or 100. Exemplary compounds that can increase the Vmax of a sirtuin include, for example, analogs of isonicotinamide, e.g., compounds of formulas 11-14 and/or analogs of O-acetyl-ADP-ribose, such as compounds of formulas 15-18. The compound may have an EC50 for activating sirtuin deacetylase activity that is less than that of daminozideAbout 1nM, less than about 10nM, less than about 100nM, less than about 1 \u03bc M, less than about 10 \u03bc M, less than about 100 \u03bc M, or about 1-10nM, about 10-100nM, about 0.1-1 \u03bc M, about 1-10 \u03bc M, or about 10-100 \u03bc M. The compound can activate the sirtuin's deacetylase activity by a factor of at least about 5, 10, 20, 30, 50, or 100, as measured in a cell-free assay or a cell-based assay described in the examples. The induction of SIRT1 deacetylase activity by this compound was at least 10%, 30%, 50%, 80%, 2-fold, 5-fold, 10-fold, 50-fold, or 100-fold greater than the induction of SIRT1 deacetylase activity by the same concentration of chenopodium album alcohol or other compounds described herein. The compound activates EC50 of SIRT5 to be at least about 10-fold, 20-fold, 30-fold, 50-fold higher than EC50 that activates SIRT 1.</p>In exemplary embodiments, the methods and compositions described herein can include combination therapies comprising (i) at least one sirtuin-activating compound that decreases the Km of a sirtuin for its substrate or NAD + by a factor of at least about 2,3, 4,5, 10, 20, 30, 50, or 100, and (ii) at least one sirtuin-activating compound that increases the Vmax of a sirtuin by a factor of at least about 2,3, 4,5, 10, 20, 30, 50, or 100. In one embodiment, the combination therapy may comprise (i) at least one sirtuin-activating compound of formulae 1-10, and (ii) at least one sirtuin-activating compound of formulae 11-18.</p>The compound may pass through the cytoplasmic membrane of the cell. For example, a compound can have a cell permeability of at least about 20%, 50%, 75%, 80%, 90%, or 95%.</p>The compounds described herein may also have one or more of the following characteristics: the compound may be substantially non-toxic to the cell or subject; the compound can be an organic molecule or a small molecule of 2000amu or less, 1000amu or less; the half-life of the compound under standard atmospheric conditions is at least about 30 days, 60 days, 120 days, 6 months or 1 year; the half-life of the compound in solution may be at least about 30 days, 60 days, 120 days, 6 months, or 1 year; the compound may be at least about 50%, 2-fold, 5-fold, 10-fold, 30-fold, 50-fold, or 100-fold more stable in solution than cannelinol; the compound can promote "
]